TY - JOUR
T1 - Fecal microbiota transplantation for gastrointestinal diseases
AU - Matsuoka, Katsuyoshi
AU - Mizuno, Shinta
AU - Hayashi, Atsushi
AU - Hisamatsu, Tadakazu
AU - Naganuma, Makoto
AU - Kanai, Takanori
N1 - Publisher Copyright:
© 2014 by The Keio Journal of Medicine.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.
AB - Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.
KW - Clostridium difficile
KW - Crohn’s disease
KW - Gut microbiota
KW - Transplantation
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=84920541630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920541630&partnerID=8YFLogxK
U2 - 10.2302/kjm.2014-0006-RE
DO - 10.2302/kjm.2014-0006-RE
M3 - Review article
C2 - 25500625
AN - SCOPUS:84920541630
SN - 0022-9717
VL - 63
SP - 69
EP - 74
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
IS - 4
ER -